ArticleBMC cardiovascular disorders2026
Association of GlyCD147 with carotid atherosclerosis: evidence from integrative analyses.
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundAtherosclerosis is an inflammatory cardiovascular disease that progresses with ageing. Glycosylation plays a significant role in inflammation and contributes to the pathogenesis of ageing-related diseases, including atherosclerosis. Cluster of differentiation 147 (CD147), a glycosylated agonist of matrix metallopeptidase 9 (MMP9), serves as an inducer of atherosclerosis and atherothrombosis. However, the effect of glycosylated CD147 (GlyCD147) on atherosclerosis remains unclear. This research aims to identify whether GlyCD147 is associated with atherosclerosis.
methodsTo begin with, a clinical case-control study was designed to assess the differences of CD147 and GlyCD147 between 69 carotid atherosclerosis (CAS) cases and 69 controls. Traditional atherosclerotic risk factors, including age, gender, smoking, alcohol consumption, hypertension, type 2 diabetes mellitus (T2DM), dyslipidemia and obesity, between cases and controls were matched by propensity score matching. Next, a cross-sectional study including 583 participants was conducted to confirm the association of GlyCD147 with CAS by multivariable logistic analysis, which was further examined within subgroups defined by age, gender, smoking, hypertension, T2DM and dyslipidemia. Subsequently, the differentially expressed key genes of carotid artery atheroma were identified by profiling the GSE43292 gene expression dataset.
resultsThe serum level of GlyCD147 in CAS cases was higher than that in controls [2.40 µg/L vs. 1.06 µg/L, P < 0.001], whereas no significant difference of CD147 protein level was observed. Elevated GlyCD147 was positively associated with risk of CAS (adjusted odds ratio 21.57, 95% confidence interval 13.10-35.52, P < 0.001). Especially, GlyCD147 was shown to raise risk of CAS onset across different subgroups. The top hub gene associated with CAS was MMP9 based on its high degree centrality in protein-protein interaction network, which was upregulated in atheroma plaques in comparison to the adjacent tissues.
conclusionThis research demonstrated that GlyCD147 is independently associated with CAS even with other traditional atherosclerotic risk factors being considered. A potential pathogenesis underlying this association could be that GlyCD147 may be involved in CAS by promoting an MMP9-mediated inflammatory response, a hypothesis that warrants future validation through functional experiments.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.